Key Takeaways from R&D Day 2026: From the Device Renaissance to Enlightenment
Orchestra BioMed Investor Relations Blog | November 2026
News & Events
Nov 19, 2026, 9:29:59 AM / by Orchestra BioMed posted in Corporate
Orchestra BioMed Investor Relations Blog | November 2026
Oct 27, 2026, 11:23:21 AM / by Orchestra BioMed posted in Corporate
Orchestra BioMed Investor Relations Blog | October 2026
Oct 9, 2026, 3:39:05 PM / by Orchestra BioMed posted in Corporate
Sep 29, 2026, 9:03:53 AM / by Orchestra BioMed posted in Corporate
Sep 23, 2026, 12:54:55 PM / by Orchestra BioMed posted in Corporate
Orchestra BioMed Investor Relations Blog | September 2026
Sep 10, 2026, 12:15:00 AM / by Orchestra BioMed posted in Corporate
Aug 18, 2026, 9:51:16 AM / by Orchestra BioMed posted in Corporate
Orchestra BioMed Investor Relations Blog | August 2026
Orchestra BioMed recently announced financial results for the second quarter of 2026 and provided a business update across our two pivotal-stage cardiovascular programs. The quarter delivered meaningful clarity on the timeline for primary endpoint results from the BACKBEAT global pivotal trial (“BACKBEAT Trial”) as well as planned regulatory submissions for AVIM Therapy, assuming endpoints are met. We also continued to advance the Virtue SAB in the Treatment of Coronary In-Stent Restenosis Trial (“Virtue Trial”), our investigational device exemption (IDE) randomized pivotal trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis. At the same time, we strengthened our financial foundation to support both programs through their next major milestones.
Mar 2, 2026, 10:27:08 AM / by Orchestra BioMed posted in Corporate
The recent acquisition of Vivasure Medical by Haemonetics follows over a decade of collaboration between Vivasure and Orchestra BioMed. Over that time, Orchestra worked alongside the Vivasure team through early-stage fundraising, clinical development and next-generation advancement of the PerQseal® technology, including during the formation and evolution of Vivasure’s strategic relationship with Haemonetics.
Dec 22, 2025, 10:59:59 AM / by Orchestra BioMed posted in Corporate
As 2025 comes to a close, I want to take the opportunity to reflect on a year of important achievements that puts Orchestra BioMed in a very strong position for the year to come. This year saw our Company make substantive clinical, strategic, and financial progress: we advanced execution of both of our pivotal trial-stage programs, we strengthened and clarified our strategic partnerships, and we secured nearly $150 million in capital and capital commitments on favorable terms.
Dec 2, 2025, 11:00:00 AM / by Orchestra BioMed posted in Corporate
To complement our two-part summary of Orchestra BioMed’s recent shareholder update call, we are highlighting the Q&A session that followed the prepared remarks. Given strong shareholder interest in the types of questions asked - and the additional clarity provided by management during the discussion - we believe a concise summary of the major themes will be helpful.
© 2026 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01